Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BMRA 
Biomerica Inc (BMRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BMRA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -85.09% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.02M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) - | Beta 0.33 | 52 Weeks Range 1.93 - 8.80 | Updated Date 06/29/2025 |
52 Weeks Range 1.93 - 8.80 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -85.42% | Operating Margin (TTM) -108.13% |
Management Effectiveness
Return on Assets (TTM) -35.99% | Return on Equity (TTM) -72.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5377116 | Price to Sales(TTM) 1.41 |
Enterprise Value 5377116 | Price to Sales(TTM) 1.41 | ||
Enterprise Value to Revenue 0.95 | Enterprise Value to EBITDA -5.42 | Shares Outstanding 2545760 | Shares Floating 2384045 |
Shares Outstanding 2545760 | Shares Floating 2384045 | ||
Percent Insiders 10.13 | Percent Institutions 5.8 |
Upturn AI SWOT
Biomerica Inc
Company Overview
History and Background
Biomerica Inc. was founded in 1971. Initially focused on allergy testing, the company has evolved to specialize in gastrointestinal disease diagnostics and treatments. It has grown through product development and strategic acquisitions.
Core Business Areas
- Gastrointestinal Disease Diagnostics: Develops and commercializes diagnostic tests for gastrointestinal diseases like Irritable Bowel Syndrome (IBS) and Helicobacter pylori (H. pylori).
- Gastrointestinal Disease Treatments: Offers treatment options such as InFoods IBS, a diagnostic-guided dietary management for IBS.
Leadership and Structure
Zackary Irani is the Chairman, President, and CEO. The company has a typical corporate structure with departments focusing on R&D, sales and marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- hp+detect: A rapid point-of-care test for H. pylori infection. Market share data is difficult to definitively ascertain due to the fragmented nature of the rapid diagnostic market. Competitors include companies offering similar rapid tests and laboratory-based H. pylori testing services. Revenue for diagnostic business was $5.5M for fiscal year 2023.
- InFoods IBS: A diagnostic-guided dietary management program for IBS. Market share is limited as it represents a relatively new and niche approach to IBS management. Competitors include pharmaceutical companies offering IBS drugs (e.g., AbbVie with Linzess, Salix Pharmaceuticals with Xifaxan) and companies offering other dietary management plans.
- EZ Detect: A self-administered fecal occult blood test (FOBT) for the detection of colorectal cancer. Market share data not easily available. Primary competitors include Exact Sciences(EXAS) with its Cologuard test and other FOBT products.
Market Dynamics
Industry Overview
The diagnostics market is growing, driven by increased awareness of gastrointestinal disorders and the desire for non-invasive testing options. The treatment market for IBS and related conditions is also expanding, fueled by a growing aging population and increased diagnosis rates. A growing aging population with increasing GI disorders is also on the rise.
Positioning
Biomerica is positioned as a player focused on GI health. Their competitive advantage lies in its specialized diagnostic tests and dietary management programs for IBS. The competitive advantage is that it is non-invasive and easily accessible.
Total Addressable Market (TAM)
The TAM for gastrointestinal diagnostics and therapeutics is estimated to be in the billions of dollars. Biomerica is positioned to capture a portion of this market with its innovative products, but it faces significant competition from larger players. The IBS market is expected to be worth $7.4B by 2032.
Upturn SWOT Analysis
Strengths
- Specialized focus on gastrointestinal health
- Proprietary diagnostic technologies
- Established sales and distribution network
- Revenue Growth 2023 and 2024
Weaknesses
- Limited financial resources compared to larger competitors
- Reliance on a small number of key products
- Marketing and sales need improvements.
Opportunities
- Expanding product line through R&D and acquisitions
- Entering new geographic markets
- Partnering with larger healthcare organizations
- Increased IBS awareness and diagnosis
Threats
- Competition from larger diagnostic and pharmaceutical companies
- Regulatory changes
- Reimbursement challenges
- Economic downturns reducing healthcare spending
Competitors and Market Share
Key Competitors
- EXAS
- ABBV
- ALKS
Competitive Landscape
Biomerica faces intense competition from larger, more established companies. Its success depends on its ability to innovate and differentiate its products in the marketplace.
Growth Trajectory and Initiatives
Historical Growth: Biomerica has experienced moderate growth in recent years, driven by increased sales of its key products and strategic expansion efforts. They are expected to have a year of revenue growth.
Future Projections: Analyst estimates project continued revenue growth for Biomerica, driven by expanding market penetration and new product launches. Biomerica is expected to be breakeven in the next 2 to 3 years.
Recent Initiatives: Recent initiatives include expanding the sales force, investing in R&D, and seeking regulatory approvals for new products.
Summary
Biomerica Inc. is a specialized player in the gastrointestinal diagnostics and treatment market, with a focus on IBS and H. pylori. While it faces competition from larger companies, its proprietary technologies and focus on niche markets offer growth opportunities. It has shown good growth in recent years. It needs to focus on controlling costs. Investors need to be aware that there is significant risk in the stock due to the size and the competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Third party financial data providers
- Industry reports
- Company press releases
- Company financial results
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomerica Inc
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2005-01-03 | CEO & Director Mr. Zackary S. Irani | ||
Sector Healthcare | Industry Medical Devices | Full time employees 64 | Website https://www.biomerica.com |
Full time employees 64 | Website https://www.biomerica.com | ||
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops, markets, and sells COVID-19 diagnostic tests to indicate if a person has been infected by COVID-19. The company was incorporated in 1971 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.